The strategic-level alliance will see UK-headquartered Exscientia take the 15 projects from target identification, drug design and lead optimisation, with Sanofi taking over at the preclinical ...

The combined company would advance significant therapeutic collaborations with prominent biopharma companies, including Sanofi ... in revenue before royalties. Exscientia shareholders are set ...

Exscientia also has a really substantial collaboration [oncology and immunology/inflammation, up to $5.2 billion, launched in 2022] with Sanofi. What’s most exciting is, those are all future ...

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi is following several of its big pharma industry peers into radiopharmaceuticals, striking a deal for a clinical-stage therapy now in discussion for a regulatory submission as a treatment ...

By Ludwig Burger (Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive ...

But, in the GEMINI trials, tolebrutinib failed the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when it came to reducing relapses over up to 36 months. Trying to find the ...

Sanofi has temporarily stopped distributing and selling its flu shots in China out of concerns of waning potency. A Sanofi spokesperson confirmed the halt to Fierce Pharma. Supplies of the French ...

The strategic-level alliance will see UK-headquartered Exscientia take the 15 projects from target identification, drug design and lead optimisation, with Sanofi taking over at the preclinical ...